Open AccessIn Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile
Author(s) -
Daisuke Oka,
Naomitsu Yamaya,
Toshiki Kuno,
Yuta Asakawa,
Toshiyuki Shiragiku,
Liang Chen,
Xue Jingbo,
Abudusaimi Mamuti,
Fangguo Ye,
Jiangqin Sun,
Kinue Ohguro,
Hisashi Miyamoto,
Yukitaka Uematsu,
Katsuya Inagaki,
JieFei Cheng,
Makoto Matsumoto
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01170-20
Subject(s) - fidaxomicin , vancomycin , in vivo , microbiology and biotechnology , pharmacology , antibiotics , minimum inhibitory concentration , chemistry , medicine , biology , bacteria , genetics , staphylococcus aureus
OPS-2071 is a novel quinolone antibacterial agent characterized by low oral absorption that reduces the risk of adverse events typical of fluoroquinolone class antibiotics. The in vitro and in vivo antibacterial activities of OPS-2071 against Clostridioides difficile were evaluated in comparison to vancomycin and fidaxomicin.